Orthostatic Hypotension and Cardiovascular Risk

Cyndya Shibao, Italo Biaggioni

See related article, pp 1054–1059

Orthostatic hypotension (OH) results from a failure of neural and circulatory mechanisms to compensate for the reduction in venous return that normally occurs on assuming the upright posture. OH is defined as a fall in systolic blood pressure of ≥20 mm Hg or diastolic blood pressure of ≥10 mm Hg measured within 3 minutes of standing.1 OH can result from 6% and 35% or more, depending on the age group and associated comorbidities.2,3 During the past 2 decades, evidence from cross-sectional and longitudinal epidemiological studies has identified OH as an independent risk factor for cardiovascular morbidity and all-cause mortality.4 In prospective studies, the presence of OH at baseline increased the risk of subsequent adverse outcomes, including stroke,5 coronary heart disease,6 and all-cause mortality.2,4,7,8 In this issue of the journal, Franceschini et al9 have added chronic kidney disease to the list of adverse health outcomes associated with OH. The authors examined the previously reported Atherosclerosis Risk in Communities cohort and found that the presence of OH at baseline increases the risk of subsequent development of chronic kidney disease, particularly in blacks, after accounting for known risk factors for chronic kidney disease including diabetes and hypertension. The Figure compares the risk of developing end-stage renal disease attributed to OH, with other risk factors reported previously in the same cohort.10 It is noteworthy that the presence of OH imparts a risk comparable to or greater than other factors that elicit greater awareness and that are managed more aggressively.

Given the impact of OH, it would seem important to identify it in clinical practice. Blood pressure is typically measured in the seated posture in the clinic. Adding an upright blood pressure measurement to an office visit would seem a trivial undertaking, but we suspect it is not often done. The definition of OH, and the evidence of it as a risk factor, is based on supine to standing blood pressures, which would be even more difficult to implement. Seated to upright measurements may not be validated in outcome trials but offer the best hope for detection of OH.

It would be easier to justify routine orthostatic blood pressure measurements if there was an intervention that would prevent OH or its consequences. In this regard, it is important to examine the risk factors that lead to OH and the potential mechanisms by which it is associated with bad outcomes. It has been argued that the wide swings in blood pressure associated with OH could by themselves contribute to end-organ damage. Indeed, patients with autonomic failure characterized by supine hypertension and severe OH have decreased renal function compared with controls.11 However, even in this extreme clinical condition it is not clear whether the large blood pressure variations seen in these patients are to blame or if supine hypertension is sufficient to explain these alterations.

The largest determinant of OH is aging.12 The incidence of OH increases from <5% in the fifth decade of life to ~20% at ≥70 years of age. Other risk factors include hypertension, diabetes, Parkinson’s disease, and carotid arterial disease. All these risk factors have in common the potential to impair autonomic mechanisms that regulate blood pressure. In particular, baroreflex function is decreased in these conditions. Depressed baroreflex sensitivity has been associated with an increased risk of cardiovascular morbidity and mortality.13,14 Decreased high-frequency variability of heart rate, another index of impaired autonomic function, is also an independent risk factor for cardiovascular mortality. We are not aware of epidemiological studies that examined the association between OH and baroreflex sensitivity or heart rate variability, but the evidence points toward an impairment of autonomic function playing a role in the adverse outcomes associated with OH.

Identifying interventions that would improve autonomic function, avoid OH, or prevent its negative consequences remains a challenge. Pharmacological treatment of symptomatic OH involves mineralocorticoids and pressor agents, but these would be counterproductive in asymptomatic OH and unlikely to improve outcomes. Physical countermeasures (eg, compression stockings) and lifestyle changes (weight reduction or exercise) are attractive options, but their efficacy is unproven, and compliance is
likely to be poor in asymptomatic patients. Improving vascular disease with better control of hypertension, hyperglycemia, and hyperlipemia should already be part of the management of these patients, but treatment directed at these conditions may not necessarily improve OH and can even induce or worsen it. The one potential intervention at our disposal would be to avoid medications known to be associated with OH (eg, diuretics or adrenergic blockers) or to impair autonomic function. Unfortunately there is little evidence-based information that could justify specific guidelines.

In summary, asymptomatic OH is a significant medical problem, particularly in the elderly. As our population ages, the importance of OH as a health care burden is likely to increase. Impaired autonomic function probably contributes to the development of OH and may play a role in its negative consequences. It would be valuable to determine whether the presence of OH correlates with noninvasive indices of impaired autonomic function (eg, baroreflex sensitivity and heart rate spectral analysis). It is likely that asymptomatic OH remains unrecognized in the majority of patients in clinical practice. An effort should be made to detect OH in patients at risk (elderly, patients with hypertension, diabetes mellitus, or Parkinson’s disease, or receiving multiple medications). Research is needed to determine interventions that may prevent OH or the adverse outcomes associated with it.

**Sources of Funding**
This work was supported in part by grant P01 HL056693, Autonomic Rare Diseases Clinical Research Consortium grant U54 NS065736, the Vanderbilt Clinical and Translational Science Award grant UL1 RR024975 from the National Center for Research Resources, and the National Institutes of Health. C.S. is supported by grant K23 HL103976 from the National Institutes of Health and grant 10CRP4310026 from the American Heart Association Clinical Research Program.

**References**

**Disclosures**
None.

**Figure.** Hazard ratio/relative risk (and 95% CI) of developing end-stage renal disease associated with OH at baseline or other risk factors. All data are from the Atherosclerosis Risk in Communities cohort. End-stage renal disease was defined by renal replacement with dialysis or kidney transplant.


Orthostatic Hypotension and Cardiovascular Risk
Cyndya Shibao and Italo Biaggioni

Hypertension. 2010;56:1042-1044; originally published online November 8, 2010;
doi: 10.1161/HYPERTENSIONAHA.110.162768

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://hyper.ahajournals.org/content/56/6/1042

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/